This shows you the differences between two versions of the page.
| Both sides previous revision Previous revision Next revision | Previous revision |
| drugs_cystic_fibrosis [2026/08/03 11:09] – [Practical Monitoring Approach] Scott Larson | drugs_cystic_fibrosis [2026/08/03 11:13] (current) – [References] Scott Larson |
|---|
| - [[https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/212273s004lbl.pdf|Trikafta. Food and Drug Administration. Updated date: 2026-06-22]] | - [[https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/212273s004lbl.pdf|Trikafta. Food and Drug Administration. Updated date: 2026-06-22]] |
| - [[https://www.nejm.org/doi/10.1056/NEJMra2216474|Cystic Fibrosis. Grasemann H, Ratjen F. The New England Journal of Medicine. 2023;389(18):1693-1707]] | - [[https://www.nejm.org/doi/10.1056/NEJMra2216474|Cystic Fibrosis. Grasemann H, Ratjen F. The New England Journal of Medicine. 2023;389(18):1693-1707]] |
| - Cystic Fibrosis. Ong T, Ramsey BW. JAMA. 2023;329(21):1859-1871. doi:10.1001/jama.2023.8120 | - [[https://pubmed.ncbi.nlm.nih.gov/37278811/|Cystic Fibrosis. Ong T, Ramsey BW. JAMA. 2023;329(21):1859-1871]] |
| - Heterogeneity in Reported Side Effects Following Initiation of Elexacaftor‐Tezacaftor‐Ivacaftor: Experiences at a Quaternary CF Care Center. Papadakis L, Stander T, Mombourquette J, et al. Pediatric Pulmonology. 2025;60(1):e27382. doi:10.1002/ppul.27382. | - [[https://pubmed.ncbi.nlm.nih.gov/39503182/|Heterogeneity in Reported Side Effects Following Initiation of Elexacaftor‐Tezacaftor‐Ivacaftor: Experiences at a Quaternary CF Care Center. Papadakis L, Stander T, Mombourquette J, et al. Pediatric Pulmonology. 2025;60(1):e27382]] |
| - [[https://www-bmj-com.proxy.lib.uiowa.edu/content/361/bmj.k1783|Review Article]] | - [[https://pmc.ncbi.nlm.nih.gov/articles/PMC2137053/|Cystic Fibrosis. Davies JC et al. BMJ 2007;335(7632):1255–1259]] |
| |
| {{tag>drugs}} | {{tag>drugs}} |